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A previous unbiased genome-wide analysis of CD4Mycobacterium
tuberculosis (MTB) recognition using peripheral blood mononu-
clear cells from individuals with latent MTB infection (LTBI) or non-
exposed healthy controls (HCs) revealed that certain MTB se-
quences were unexpectedly recognized by HCs. In the present
study, it was found that, based on their pattern of reactivity, epi-
topes could be divided into LTBI-specific, mixed reactivity, and
HC-specific categories. This pattern corresponded to sequence con-
servation in nontuberculous mycobacteria (NTMs), suggesting envi-
ronmental exposure as an underlying cause of differential re-
activity. LTBI-specific epitopes were found to be hyperconserved, as
previously reported, whereas the opposite was true for NTM con-
served epitopes, suggesting that intragenus conservation also influ-
ences host pathogen adaptation. The biological relevance of this
observation was demonstrated further by several observations. First,
the T cells elicited by MTB/NTM cross-reactive epitopes in HCs were
foundmainly in a CCR6+CXCR3+memory subset, similar to findings in
LTBI individuals. Thus, both MTB and NTM appear to elicit a pheno-
typically similar T-cell response. Second, T cells reactive to MTB/NTM-
conserved epitopes responded to naturally processed epitopes from
MTB and NTMs, whereas T cells reactive to MTB-specific epitopes
responded only to MTB. Third, cross-reactivity could be trans-
lated to antigen recognition. Several MTB candidate vaccine anti-
gens were cross-reactive, but others were MTB-specific. Finally,
NTM-specific epitopes that elicit T cells that recognize NTMs but
not MTB were identified. These epitopes can be used to character-
ize T-cell responses to NTMs, eliminating the confounding factor of
MTB cross-recognition and providing insights into vaccine design
and evaluation.
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The group Actinobacteria contains the large genus Mycobac-teria that includes not only the causative agent of tubercu-
losis, Mycobacterium tuberculosis (MTB), part of the MTB
complex, but also Mycobacterium leprae and nontuberculous
Mycobacteria (NTMs; also known as “environmental Mycobac-
teria,” “atypical Mycobacteria,” and “Mycobacteria other than
tuberculosis”) (1, 2).
MTB-derived epitopes recognized by human T cells have been
shown to be hyperconserved relative to the rest of the genomes
of the MTB complex (3). This hyperconservation suggests that
these epitopes may act as decoys, diverting the immune response
from recognizing more relevant MTB proteins and thereby fa-
voring MTB persistence (4). However, the immunological con-
sequence of the conservation of MTB sequences across other
species of the Mycobacteria genus has received less attention at
the level of the specific epitopes.
Several observations suggest reactivity to MTB in nonexposed
[non–bacillus Calmette–Guérin (bCG)-vaccinated and non–MTB-
infected) individuals. For example, a population in Malawi with no
history or scar evidence of prior bCG vaccination or MTB infection
showed responsiveness to a variety of mycobacterial antigens and
purified protein derivative (PPD) from different NTMs (5, 6). In
addition, non–MTB-infected and non–bCG-vaccinated individuals
respond to MTB-encoded antigens, MTB lysate, and PPD (7, 8).
In particular, NTMs are a ubiquitous and heterogeneous group
of environmental microorganisms found in soil, fresh water (in-
cluding tap water), and seawater (9–12). Although several very
rarely cause disease, most NTMs are opportunistic pathogens of
humans, animals, poultry, and fish (9, 12, 13). Their prevalence in
the environment results in regular human exposure to different
species via different routes, and NTMs can be detected in the re-
spiratory and gastrointestinal tract or on the skin of healthy indi-
viduals (12). This environmental exposure can influence resistance
to MTB as well as interfere with or enhance the protective immune
response to vaccination (14). Several lines of evidence suggest that
differences in exposure to NTMs may be an important determinant
of the variation in efficacy observed with bCG vaccination (15, 16).
Although there is substantial evidence for immune cross-
reactivity between MTB and NTM bacteria (15–18), no studies
have been performed at the level of the specific epitopes.
Analyses of immune responses induced by NTM infection are
limited, and the lack of NTM-specific reagents further compli-
cates this issue. Several reports suggest that NTMs induce the
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production not only of IFN-γ but also of TNF-α, IL-1β, and IL-6
(19-21). NTM-specific reagents to monitor influence of NTM ex-
posure would be important for vaccine evaluations, development,
and diagnostics alike.
Here, using data available from a genome-wide screen for
MTB-derived epitopes, we characterized the response in individ-
uals with latent MTB infection (LTBI) and nonexposed healthy
controls (HCs) and investigated the role of epitope conservation.
We found not only that HCs reacted to sequences derived from
MTB but also that this reactivity correlated with conservation in
NTMs and was mediated by the same CD4+CCR6+CXCR3+
memory T-cell subset as in LTBI donors. Differential reactivity of
the epitopes also extended to MTB and NTM epitopes generated
by natural processing by antigen-presenting cells. In addition, we
defined a set of NTM-specific epitopes not present in MTB.
These findings have implications for the design and evaluation of
vaccine candidates and diagnostic applications.
Results
Differential Reactivity of TB-Specific Epitopes in HC Individuals. We
previously reported a genome-wide screen of MTB-derived pre-
dicted CD4 T-cell epitopes in LTBI donors (22). In that study
MTB-uninfected/non–bCG-vaccinated donors recruited in the gen-
eral San Diego area were used as HCs. For reference purposes,
a summary of those already-published data are shown in Fig. 1A.
Although the LTBI donors had a strong reactivity against se-
lected epitopes, some degree of reactivity also was observed in
the HC donors (22).
In the present study, we set out to analyze in more detail the
differential patterns of reactivity in LTBI and HC individuals.
Specifically, epitopes recognized by two or more donors were
divided into different categories based on their recognition by
these donor cohorts (Fig. 1B). LTBI-specific epitopes (those for
which no reactivity was observed in any of the 31 HC donors
tested) accounted for 72% of the epitopes and 62% of the total
reactivity. Mixed epitopes (for which some reactivity was ob-
served in both LTBI and HC donors) accounted for 21% of the
epitopes and 36% of the reactivity. Interestingly, a few epitopes,
which accounted for 7% of the epitopes and 2% of the reactivity,
were recognized exclusively by HC individuals (HC-specific).
Differentially Reactive Epitopes also Are Differentially Conserved
Within MTB Sequences. Previous work suggested that MTB epi-
topes are hyperconserved and that this conservation results from
host–pathogen coadaptation (3). Following a methodology sim-
ilar to that of Comas et al. (3), we evaluated the degree of
conservation in different epitope groups: 112 LTBI-specific, 33
mixed, and 10 HC-specific. Nonsynonymous (dN) and synony-
mous (dS) substitutions were compared to assess the relative
degree of sequence conservation in the antigens’ epitope and
nonepitope regions.
For LTBI-specific epitopes the dN/dS values for all regions
were less than 1 (Fig. 1C), indicating that purifying selection
plays a major role in the evolution of these regions. When the
dN/dS values were compared among different genomic regions,
it was confirmed that these epitopes are more conserved than are
antigens and nonepitopes (Fig. 1C), similar to the previous study of
Comas et al. (3).
Strikingly, no synonymous nucleotide substitutions were pres-
ent in the mixed and HC-specific epitopes. Analysis of the
nonsynonymous nucleotide substitution rates indicated that these
epitopes are more variable than are antigens as a whole and
nonepitopes (Fig. 1 D and E). In fact, in the case of HC-specific
epitopes, they are significantly less conserved than are antigens
and nonepitopes (Fig. 1E).
Taken together, these data indicate that the LTBI-specific
epitopes are hyperconserved and that the opposite is true for the
epitope sequences for which reactivity is detected in HCs.
Differential Reactivity Correlates with Conservation in NTM. We
further hypothesized that the pattern of reactivity presented
above might result from exposure to NTMs and that the re-
activity seen in HCs might be directed against epitopes con-
served in these strains. To test this hypothesis, we retrieved all
complete NTM genome sequences that were publicly available
at the time of analysis initiation (January 2012). A total of 15 NTM
species were selected: M. abscessus, M. avium 104, M. avium sub-
species paratuberculosis k 10,M. gilvum PYR-GCK,M.marinumM,
M. smegmatis strain MC2 155, M. sp. JDM601, M. sp. JLS,
M. sp. KMS, M. sp. MCS, M. sp. Spyr1 (gilvum), M. ulcerans
Agy99, M. vanbaalenii PYR-1, M. colombiense CECT 3035, and
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Fig. 1. Differential reactivity of epitopes in HC individuals. (A) Magnitude of epitope pool responses following genome-wide screen in individuals with LTBI
(n = 22) and HC (n = 20). Each dot represents one donor; median ± interquartile range is indicated. ***P < 0.001, one-tailed Mann–Whitney test. (B) Epitopes
recognized by two or more LTBI (black bars) and HC (red bars) donors divided into three categories of reactivity: LTBI-specific, mixed, and HC-specific. (C) dN/dS
in LTBI-specific epitopes compared with nonepitope regions and antigens as a whole. ****P < 0.0001; Mann–Whitney test. (D and E) dN in mixed (D) and
HC-specific (E) epitopes compared with nonepitope regions and antigens as a whole. ***P < 0.001; Mann–Whitney test. ns, no significant difference.
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M. parascrofulaceum ATCC BAA-614. Next, the sequences of
the 155 epitopes from Fig. 1B were compared with these full-
genome sequences. The number of genomes in which each epitope
was conserved was tabulated for each of the epitope classi-
fications. To allow for likely cross-reactivity at the immunological
level of closely related sequences, a single substitution was allowed
per epitope.
The results of this analysis are shown in Fig. 2A. The LTBI-
specific epitopes were clearly associated with low conservation,
being found, on average, in 1.7 (11%) of the 15 NTM genomes,
whereas the mixed epitopes were conserved in a significantly
higher number (3.3, 22%; P = 0.016, unpaired t test). Even more
strikingly, however, on average the HC-specific epitopes were
conserved in almost 50% of the 15 genomes analyzed (P < 0.0001).
The number of epitopes conserved in each strain appeared to
correlate with how closely related the strains are in the phylogenetic
tree. The highest numbers of instances of conservation were ob-
served in M. marinum and M. ulcerans, which also are most closely
related to MTB.
In conclusion, these results suggest that HCs cross-recognize
MTB sequences and that this recognition correlates with the
conservation of those sequences in NTMs.
Differential Recognition of Epitope Pools Based on Their Genus-Wide
Conservation Features. Next, we undertook the converse experi-
ment to test whether conservation across different mycobacteria
species directed the specificity of recognition in different donor
cohorts. Epitopes from Fig. 1B were classified into those found
only in MTB (55 epitopes) and those also conserved in NTMs
(69 epitopes) (Dataset S1). Epitope conservation in 44 classes of
bacteria other than Mycobacterium was determined also, and
these 51 broadly conserved epitopes were analyzed separately
(Dataset S1). To maximize signal strength, pools containing
broadly conserved epitopes included all epitopes identified, not
only epitopes recognized by two or more donors (22).
Pools of ∼20 epitopes each were prepared and then tested
for reactivity in 20 LTBI donors and 20 HCs. The total re-
sponse per donor observed for the various epitope categories is
shown in Fig. 2B.
As expected, significantly higher reactivity was detected in
LTBI donors than in HCs, for both the MTB-only and the MTB/
NTM-conserved pools. Significantly more reactivity was directed
toward MTB/NTM-conserved sequences, suggesting that NTM
exposure may boost the reactivity to conserved sequences. Con-
versely, for HC individuals, a trend toward higher responses was
noted for the pools of epitopes conserved in NTMs.
Interestingly, for both LTBI and HC individuals the detected
reactivity against broadly conserved epitopes was significantly
less than that to MTB/NTM-conserved sequences. Very broad
conservation of a peptide from MTB in other species could mean
that it is conserved in the human proteome as well, so that lack of
reactivity to the peptide in humans could be a consequence of
self-tolerance. To examine this possibility, we compared the se-
quences of the peptides broadly conserved in other bacterial
genomes with the human proteome. Less than 0.1% of these
peptides were found to be conserved in humans, suggesting that
mechanisms other than self-tolerance must underlie this effect.
The Antigenic Basis of Differential Reactivity. The data presented
above imply that in a population with low exposure to the MTB
complex, such as our donor cohort from the general San Diego
area, preexisting immunity and occasional boosting might be
provided by exposure to NTMs. In terms of vaccine design or
evaluation, preexisting immunity might be viewed as desirable.
Alternatively, in the context of the evaluation of vaccination
strategies, preexisting immunity may contribute an undesired
confounding factor. In this respect, the fact that the different
epitope classes appear to be differentially conserved raises the
possibility that they might be used differentially in pathogen-
evasion strategies.
To examine this issue, epitope reactivity data next were mapped
back to the specific antigens of provenance (22). Antigens were
categorized further as LTBI-specific or cross-reactive as described
in Materials and Methods.
Fig. 3 A and B shows the response frequency and magnitude
of antigens currently included in tuberculosis (TB) vaccines in
clinical development. As can be seen, vaccine antigens Rv0288,
Rv1886c, Rv2608, and Rv3804c are widely cross-reactive, whereas
antigens Rv1196, Rv3619c, Rv3620c, and Rv3875 appear to be
exclusively LTBI-specific. Thus, a dichotomy exists in candidate
vaccine antigens, with approximately half being classified as LTBI-
specific and half being classified as cross-reactive.
A B
Fig. 2. Differential reactivity correlates with conservation. (A) Conservation of LTBI-specific, mixed, and HC-specific epitopes in 15 NTM. *P < 0.05, ****P <
0.0001, unpaired t test. (B) Magnitude of epitope pool responses following division based on conservation in MTB or MTB/NTM or broadly conserved across
bacteria in LTBI (n = 20) and HC (n = 20) donors. Each dot represents one donor; the median ± interquartile range is indicated. The dashed line at 20 SFC
indicates the threshold of positivity. *P < 0.05, **P < 0.01, ****P < 0.0001; one-tailed Mann–Whitney test. ns, not significant.
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CD4+ T-Cell Responses to MTB/NTM-Conserved Epitopes in HC Donors
Are Restricted to the CCR6+CXCR3+ T-Cell Subset. The results pre-
sented above demonstrate that TB epitopes whose sequences are
conserved in NTMs also can be recognized by HCs. We next
used the T-cell library approach (23) to investigate whether the
T cells recognizing these sequences in HC donors are associated
with a similar or dissimilar phenotype, compared with those re-
cognizing the same sequences in LTBIs. For these experiments,
different CD4 T-cell subsets were sorted (Fig. 4 A and B), cor-
responding to CXCR3+CCR6+ cells [previously described as
identifying the majority of LTBI-derived MTB-reactive T cells
(22)], CXCR3−CCR6+ cells (enriched for Th17), and CCR6−
cells (the rest of memory T cells, enriched for Th1 and Th2).
HC-derived T cells responding to an MTB/NTM epitope pool
were highly enriched in cultures derived from the CXCR3+
CCR6+ T-cell subset (Fig. 4C). This pattern of distribution was
consistent in the three different HC donors analyzed, with 80%
of the MTB/NTM-reactive memory CD4 T-cell response re-
siding in the CXCR3+CCR6+ subset (Fig. 4D).
In conclusion, these data demonstrate that the MTB/NTM-
specific T cells responding in HC donors are largely confined
to the same CXCR3+CCR6+ subset previously described in
LTBI donors.
Definition of NTM-Specific Epitopes. Because T-cell reactivity can
be detected in HC individuals, presumably induced by exposure
to NTMs, it should be possible to identify NTM-specific epitopes
that are not conserved in MTB. To address this possibility, a total
of 1,583 predicted HLA promiscuous binders, selected as de-
scribed in Materials and Methods, were tested for ex vivo pro-
duction of IFN-γ by peripheral blood mononuclear cells (PBMCs)
from 30 HC individuals (Fig. 5A). A total of 106 individual NTM-
epitopes, not present in MTB, were identified (Fig. 5B and
Dataset S2). The top 20 epitopes account for 46% of the total
response and are conserved, on average, in 40% of the 15 NTM
strains. Individual donors recognized an average of seven epitopes
(median of 1, range 0–79), underlining the exposure rate of NTMs
in these individuals.
Next, the top 20 epitopes were pooled and tested further in
20 LTBI and 20 HC donors (Fig. 5C). As expected, the overall
frequency and magnitude of response to the NTM-specific epi-
tope pool was comparable in the two donor cohorts, presumably
because both cohorts are exposed to NTMs.
Conserved NTM/MTB and NTM-Specific Epitopes Are Generated by
Natural Processing of NTM Antigens. To demonstrate that the
patterns of sequence conservation reflect the patterns of speci-
ficity observed in antigens derived from living bacteria and
epitopes generated by natural processing, we again used the
T-cell library approach. CCR6+CXCR3+ T-cell libraries reactive to
M. tuberculosis, M. avium subspecies paratuberculosis, M. marinum,
M. avium, and M. abscessus were established by expansion with
heat-killed bacteria from these five representative mycobacterial
strains (Fig. 6A) in three representative HC donors. Significant
baseline reactivity against both MTB and NTMs exists in HCs and
was detected by this approach.
Next, we investigated whether these mycobacteria-specific
cultures recognized the MTB/NTM-conserved or NTM-specific
epitope pools. For this purpose, T-cell libraries first were ex-
panded using MTB or pooled representative NTM whole-cell
bacteria (i.e., M. abscessus, M. avium, and M. avium subspecies
paratuberculosis). Then the cultures were challenged with the
MTB-specific, MTB/NTM-conserved, or NTM-specific peptide
pools. The results clearly showed that (i) MTB-specific epitope
pools are recognized exclusively by LTBI donors after MTB
expansion, (ii) MTB/NTM-conserved pools are recognized by
both LTBIs and HCs after MTB or NTM expansion, and (iii) the
NTM-specific pool is recognized exclusively following NTM ex-
pansion (Fig. 6B).
Conversely, we also tested CCR6+CXCR3+ T cells expanded
with the MTB/NTM-conserved (Fig. 6 C and D) or NTM-specific
epitope pools (Fig. 6D) for recognition of the five mycobacterial
strains. The MTB/NTM-specific cells proliferated in response to
all strains, whereas NTM-specific cells proliferated only upon
challenge with NTMs and not in response to MTB.
Collectively, these results demonstrate that MTB/NTM epi-
tope pool-specific T cells respond, with varying degrees of cross-
reactivity, to a variety of Mycobacteria strains and confirm that
the T-cell reactivity elicited by the NTM-pool is NTM-specific.
The results also demonstrate that the epitopes conserved in
NTMs and MTB are generated by natural processing in a variety
of different NTM bacteria.
Discussion
The Mycobacteria genus encompasses not only the well-known
MTB and related species referred to as the “MTB complex” but
also a series of other Mycobacteria, NTMs, which are closely
related and seldom are pathogenic for humans in normal con-
ditions, despite their ubiquitous presence. That these NTMs
A
B
Fig. 3. Antigenic basis of differential reactivity. T-cell reactivity in LTBI
(black bars) and HC (gay bars) donors to antigens currently included in TB
vaccine trials divided in two categories of reactivity: LTBI-specific and cross-
reactive. (A) Magnitude of response as total SFC per protein. (B) Percentage
response frequency per protein.
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might be cross-reactive with MTB-complex bacteria has been
appreciated for several years (15–18), but until now the molecular
mechanisms involved in this cross-reactivity were not addressed in
detail. Our original interest in this field was sparked by the finding
that HC (non–MTB-exposed, non–bCG- vaccinated) individuals
reacted to MTB-derived epitope sequences, albeit with lower
frequency and magnitude than did LTBI individuals. Our analysis
revealed that this background reactivity is directed against epi-
topes conserved among MTB-complex bacteria and NTMs.
Our study provides an alternative, but not conflicting, di-
mension to the analysis of sequence conservation within the MTB
species by analyzing conservation within the mycobacterial genus
as a whole, and beyond as well. Indeed, we confirm the previous
observation made by Comas et al. (3) that MTB epitopes are
hyperconserved, suggesting that these epitopes might be used by
MTB as a mechanism to generate a decoy immune response ul-
timately benefitting the bacteria. Totally unexpected was the ob-
servation that the epitopes with reactivity in both LTBI and HC
48.6
%
 C
D
4+
 m
em
or
y 
T 
ce
lls
*
*
A B
C D
60
40
20
0
CXCR3+
CCR6+
CCR6–
22.922.2
103102 104 1050
103
104
105
0
CXCR3
C
C
R
6
60
40
20
0
80
100
M
TB
/N
TM
 p
oo
l-r
ea
ct
iv
e
C
D
4+
 m
em
or
y 
T 
ce
lls
 (%
)
CXCR3+
CCR6+
6
4
2
0
8
10
20
6
4
2
0
8
10
20
6
4
2
0
8
10
20
TU49 TU54 TU56
Δ 
cp
m
 x
10
–3
CX
CR
3+ C
CR
6+
    
CC
R6
–  
CX
CR
3+ C
CR
6+
    
CX
CR
3+ C
CR
6+
    
CXCR3-
CCR6+
CXCR3-
CCR6+
CCR6–
CX
CR
3+ C
CR
6-
    
CC
R6
–  
CX
CR
3+ C
CR
6-
    
CC
R6
–  
CX
CR
3+ C
CR
6-
    
Fig. 4. MTB/NTM-specific T-cell responses in HC donors are restricted to a CXCR3+CCR6+ memory subset. (A and B) Three CD45RA−CD25−CD4+ memory T-cell
subsets from three HC donors were sorted: (i) CCR6+CXCR3+; (ii) CCR6+CXCR3−; and (iii) CCR6−. (A) Representative dot plot from one donor. (B) Median
percentages of the T-cell subsets on total CD4+ memory T cells. Error bars indicate interquartile range. n = 3. (C) T-cell libraries were set up from the sorted
subsets by polyclonal stimulation and were expanded for 3–4 wk. Libraries were analyzed for the presence of antigen-specific T cells by stimulation with the
MTB/NTM epitope pool and measurement of 3H-thymidine incorporation. Shown is proliferation (cpm) of individual cultures from three different donors.
Dotted lines represent the cutoff value. (D) Distribution of epitope pool-specific T cells in the three memory T-cell subsets. Data represent median ± inter-
quartile range from three donors. *P < 0.05; Mann–Whitney test.
15 NTM genome sequences
Selection of all possible 15-mer 
peptides NOT in 21 MTB sequences
(allowing up to 2 substitutions)
11,532,048 15-mer peptides
Prediction of HLA class II binding
Selection of peptides binding 
minimum 18/24 alleles 
1,583 peptides -159 pools
Screened in 30 non-TB, non-BCG
Deconvolution of positive pools
Epitopes
116,070 15-mer peptides
Selection of 15-mers conserved in
minimum 5/15 NTM strains 
A B C
Fig. 5. Definition of NTM-specific epitopes. (A) Summary of the steps involved in the epitope identification pipeline showing number of genomes, 15-mer
peptides, and selected peptides. (B) Identified epitopes plotted as a function of the percentage of the total response. Black dashed lines indicate the top 20
epitopes. The capped line indicates the percentage of total response captured by the top 20 epitopes. (C) T-cell reactivity in 20 LTBI and 20 HC donors to the
top 20 NTM-specific epitopes. Shown are the response frequency (Left) and the average magnitude of response ± SD for responding donors (Right).
Lindestam Arlehamn et al. PNAS Early Edition | 5 of 9
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
PN
A
S
PL
U
S
donors and conserved in NTMs are not hyperconserved. This
finding is interesting, because it implies that NTM do not use
the same T-cell recognition decoy strategy that has been hy-
pothesized for MTB. Indeed, it is possible that, rather than
acting as a decoy, the hyperconserved T-cell reactivity seen in
MTB may reflect the need to stimulate the formation of the
caseating granulomas needed for aerosol transmission of the
pathogen (24). NTMs, on the other hand, do not require caseation
(or infected hosts) for transmission, and therefore the capacity to
induce hyperconserved T-cell reactivity may not have evolved in
association with these mycobacterial species. This observation
raises the speculation that, in the setting of MTB vaccination,
aiming immune responses to MTB/NTM-conserved epitopes and
antigens that apparently are not used or are used less often as
a decoy by MTB might be more advantageous than aiming at the
hyperconserved ones.
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Fig. 6. Conserved and NTM-specific epitopes are generated by natural processing of NTM antigens. (A) Sorted CCR6+CXCR3+ T cells from three represen-
tative HC donors were polyclonally expanded and analyzed for the presence of Mycobacteria-specific T cells by stimulation with irradiated autologous
monocytes with or without heat-killed bacteria from the indicated mycobacterial strains. Shown is proliferation (cpm) of individual cultures from three
different donors. Dotted lines represent the cutoff value. (B) Cells from one HC and one LTBI donor were stimulated with MTB lysate (solid bars) or a with pool
of M. abscessus, M. marinum, and M. avium subspecies paratuberculosis lysates (hatched bars) for 5 d. CFSElo cells were sorted and restimulated with con-
served MTB-, MTB/NTM, or NTM-specific epitope pools. Shown is proliferation (cpm). (C) Cells from two HCs (filled and open circles, respectively) were
stimulated with the MTB/NTM epitope pool for 5 d. CFSElo cells were sorted and restimulated with the MTB/NTM epitope pool as a control and the indicated
whole-cell lysates from Mycobacteria. Shown is the proliferation of individual cultures. The dotted line represents the cutoff value. (D) Sorted CCR6+CXCR3+
T cells from one representative HC were stimulated with the MTB/NTM (Lower) or NTM-specific (Upper) epitope pool for 5 d. CFSElo cells were sorted and
polyclonally expanded and were analyzed for the presence of Mycobacteria-specific T cells by stimulation with irradiated autologous monocytes with or
without indicated mycobacterial strains. Shown is proliferation (cpm).
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In addition, we have shown that NTM exposure is an important
factor in shaping the immune reactivity against MTB and that
intragenus as well as intraspecies epitope conservation should be
taken into account when investigating species-specific responses.
Recent studies have shown that this conservation is important in
diverse settings, such as human herpesviruses and grass pollen
allergy (25, 26). Chiu et al. (26) showed that CD8 T cells responding
to a varicella zoster virus epitope also respond to homologous
epitopes derived from viruses as divergent as α- and γ-herpesvi-
ruses, independent of previous infection (26). Similarly, Archila
et al. (25) showed that pollen-derived cross-reactive epitopes can be
found in a wide variety of grass species. Cross-reactivity of T
cells rather than subclinical disease thus might be an explana-
tion for detectable pathogen-specific reactivity in individuals
that are negative for the pathogen.
The partial overlap with donors previously used is a limitation
of the analysis. This limitation is important to note because, al-
though it does not impact the analytic approach and extensive in
silico analysis, it most likely does affect the final list of peptides/
proteins identified as NTM-driven responses in HCs. One third
of the donor cohort are new donors not previously investigated.
Thus, the results have been at validated least partially in a dif-
ferent cohort. The final definitive list of peptides that reflect true
pathogen versus environmental responses undoubtedly will be
winnowed down in the years to come with the expansion of the
mixed category. Furthermore, the list of cross-reactive epitopes
identified herein is not exhaustive, and many more cross-reactive
epitopes are likely to exist, because the degree of sequence
identity required to activate cross-reactive T-cell responses is not
easily predictable, and highly divergent epitopes can elicit cross-
reactive responses (27). Indeed, epitope conservation can exist
between structurally unrelated antigens with little sequence ho-
mology (28–30). We found here that epitopes conserved beyond
the Mycobacteria genus are recognized less frequently than those
conserved in MTB and NTMs. This less frequent recognition was
not caused by scarcity of these broadly conserved epitopes in the
peptide library studied. An alternative explanation for this phe-
nomenon is that broad expression and conservation among dif-
ferent bacterial classes might lead to tolerization or exhaustion
of T cells specific for those sequences or to the induction of T
cells with regulatory activity. Ongoing studies are investigating
this possibility in more detail.
Our data further imply that preexisting immunity and occa-
sional boosting might be provided by exposure to NTMs, at least
in a population with low exposure to the MTB complex, such as
the one from the general San Diego area. In this context, it is
noteworthy that other studies also have reported reactivity to
MTB-encoded antigens in HCs and NTM-infected/exposed
individuals that is hypothesized to be as a result of exposure to
NTMs (7, 8, 31). Furthermore, NTM exposure may explain the
higher baseline reactivity to PPD that was found in MTB-naive
young adults as compared with children (32). Other studies
highlighted that the majority of small MTB-PPD reactions could
be attributed to NTM exposure or disease (33). Although the
likelihood is strongly suggested by T-cell reactivity, we acknowl-
edge there is no formal evidence that the HCs with positive
responses actually were exposed to NTMs. Further studies are
being planned to test individuals who have recovered from NTM
infections to confirm that they have similar reactivity. In this re-
spect, it can be pointed out that the difference in frequency of
recognition of NTM-specific versus other nonpathogenic bacterial
epitopes recognized also can be used to support this hypothesis.
Several lines of evidence suggest that differences in exposure
to environmental mycobacteria may be an important deter-
minant of the variation in efficacy observed with bCG vaccina-
tion (15, 17, 18, 34–36). NTM exposure may influence bCG
protection by providing partial protection that bCG vaccination
might improve only marginally. Exposure to NTMs might inhibit
bCG replication and thereby prevent the induction of an efficient
bCG-mediated immune response and corresponding protection
against TB (15, 37, 38). Alternatively, it is possible that natural
exposure to certain NTMs might induce an inappropriate immune
response that is boosted by the bCG vaccine (39). If certain anti-
gens were dominant in bCG vaccination but were recognized only
weakly or not at all in TB infection, a bCG vaccine lacking those
antigens might induce a more potent and cross-reactive response.
NTM-based preexisting immunity and boosting might be viewed
as desirable in the context of vaccination strategies, especially if
the response could be directed against less hyperconserved epi-
topes. Alternatively, it might contribute an undesired confounding
factor in the evaluation of vaccination strategies. One of the cross-
reactive antigens with clear reactivity detected in HCs is the
Rv3804c antigen (Ag 85A). This antigen was selected on the
basis of conservation among all mycobacterial species as a vac-
cine candidate, MVA85A (40). MVA85A recently was evalu-
ated in phase II trials in which it was used to boost bCG
vaccinees, but it failed to protect against MTB infection (41).
Interestingly, response to this antigen has not yet been shown to
be dominant following bCG vaccination in humans. The data
presented here indicate that the Rv3804c antigen may be a
rather dominant antigen in the context of NTM exposure and
thus raise the possibility that boosting bCG responses with
different antigens that are more dominant in bCG than in NTM
might lead to a different outcome.
Interestingly, the memory T cells responsible for the reactivity
in HCs have the CCR6+CXCR3+ phenotype previously de-
scribed for LTBI and PPD-reactive individuals (22, 23, 42). The
transcriptional signature of these cells shows that they express
molecular features, such as ABCB1 (MDR1), KIT (CD117),
CCR2, BAFF, and IL12RB2, thought to be relevant for con-
trolling chronic/latent infections (43). This finding predicts that
NTM-based vaccines should elicit CD4 T-cell responses pheno-
typically similar to those elicited by MTB infection.
The data presented here demonstrate that it is possible to de-
velop well-defined reagents to measure NTM exposure, thereby
addressing fundamental questions about how NTM exposure
influences the protective effect of existing and new vaccine can-
didates. Previous studies have investigated NTM exposure using
PPD derived from NTM species (33, 44) and identified certain
NTM-specific antigens (45). However, because of the degree of
sequence homology between members of the MTB complex, the
definition of entire antigens that are NTM-specific is, in general,
problematic. Instead, the approach of defining specific epitopes
allows one to dissect specific responses more easily.
In conclusion, this study describes significant reactivity to
MTB-derived epitopes in the general population that is directed
against epitopes conserved in MTB and NTMs and shows that
intragenus epitope conservation is an important issue to be
considered in addition to intraspecies epitope conservation. The
study of intragenus epitope conservation promises to provide
important insights into host–pathogen interactions, is relevant
for diagnostic applications, and also might offer insights in the
design and evaluation of MTB vaccine candidates.
Materials and Methods
Ethics Statement. Research conducted for this study was performed in ac-
cordance with approvals from the Institutional Review Board at the La Jolla
Institute for Allergy and Immunology (FWA#00000032). All donors provided
written informed consent before participation.
Study Subjects. Leukapheresis or whole-unit blood samples from 75 adults
were obtained from the La Jolla Institute for Allergy and Immunology and the
University of California, San Diego Antiviral Research Center Clinic. Donors
were classified into LTBI andHC groups based on T-spot.TB reactivity. LTBI was
confirmed by positive T-spot.TB as well as a physical examination and/or chest
X-ray that was not consistentwith active tuberculosis. None of the donors had
been vaccinated with bCG, and all HCs had a negative T-spot.TB.
Lindestam Arlehamn et al. PNAS Early Edition | 7 of 9
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
PN
A
S
PL
U
S
For the analysis of whether differential reactivity correlates with conser-
vation as demonstrated in Fig. 2B, 18 of the 20 LTBI individuals and 9 of 20
HC donors were included in our previous study (22).
Peptides. The 15-mer peptides were synthesized as crude material on a small
(1-mg) scale by Mimotopes and/or A and A. The Immune Epitope Database
submission number for the NTM peptides is 1000598.
PBMC Isolation. PBMCs were purified by density-gradient centrifugation
(Ficoll-Hypaque; Amersham Biosciences) from 100 mL of leukapheresis sam-
ple or 450 mL of whole blood, according to the manufacturer’s instructions.
Cells were cryo-preserved in liquid nitrogen suspended in FBS (Gemini Bio-
Products) containing 10% (vol/vol) DMSO.
Ex Vivo IFN-γ ELISpot Assay. ELISpot assays were performed as previously
described (22). Briefly, PBMCs were plated at a density of 2 × 105 cells per
well in 96-well plates (Immobilon-P; Millipore) coated with anti–IFN-γ (AN18;
Mabtech). PBMCs were stimulated with peptide pools (5 μg/mL), individual
peptides (10 μg/mL), phytohemagglutinin (PHA; 10 μg/mL), or medium con-
taining DMSO corresponding to the percent of DMSO in the peptide pool
dilutions. Each condition was tested in triplicate wells. Plates were incubated
at 37 °C for 20 h, after which wells were washed with PBS/0.05% (vol/vol)
Tween 20 and incubated with 2 μg/mL biotinylated anti–IFN-γ (R4-6A2;
Mabtech) for 2 h at 37 °C. Spots were developed using Vectastain ABC peroxi-
dase (Vector Laboratories) followed by 3-amino-9ethylcarbazole (Sigma-Aldrich)
and Vector Blue Alkaline Phosphatase Substrate Kit III (Vector Laboratories).
Spots were counted using computer-assisted image analysis (KS-ELISPOT reader;
Zeiss). For a response to be considered positive, three criteria had to be fulfilled:
net spot-forming cells (SFC) per 106 ≥20, stimulation index ≥2 (sample divided by
negative control), and P < 0.05 (mean of triplicate values of the sample vs. the
negative control; Student’s t test).
T-Cell Library. T-cell library assays were performed as previously described
(23). CD4 T cells were isolated from PBMCs by positive selection with
microbeads (Miltenyi Biotec). Memory CD4+ T-cell subsets were sorted with
a FACSAria (BD Biosciences) to over 98% purity excluding CD45RA+, CD25+,
CD8+, CD19+, and CD56+ cells. Antibodies used for positive selection were
anti–CCR6-PE (11A9; BD Pharmingen), anti–CCR4-PE-Cy7 (1G1; BD Pharmin-
gen) and anti–CXCR3-APC (G025H7; BioLegend). Cells were cultured in RPMI
1640 medium supplemented with 2 mM glutamine, 1% (vol/vol) nonessential
amino acids, 1% (vol/vol) sodium pyruvate, penicillin (50 U/mL), streptomycin
(50 μg/mL) (all from Invitrogen), and 5% (vol/vol) heat-inactivated human se-
rum (Swiss Red Cross). T cells (1,000 cells per well) were stimulated polyclonally
with 1 μg/mL PHA (Remel) in the presence of irradiated (45 Gy) allogeneic
feeder cells (1.0 × 105 cells per well) and IL-2 (500 IU/mL) in a 96-well plate
format, and T-cell lines were expanded as previously described (23). Library
screening was performed at day 14–21 by culturing extensively washed
T cells (∼2.5 × 105 cells per well) with irradiated autologous monocytes
(2.5 × 104), either unpulsed or pulsed for 3 h with Mycobacteria whole
particles (ratio 1:3). Microbes were killed by heating at 95 °C for 10 min
according to standard methods. In some experiments, T cells were cultured
with peptide pools (2 μg/mL). Proliferation was measured on day 2 or 3
after 16-h incubation with 1 μCi/mL [methyl-3H]-thymidine (Perkin-Elmer).
Precursor frequencies were calculated based on numbers of negative wells
according to the Poisson distribution and are expressed per million cells.
In some experiments, carboxyfluorescein succinimidyl ester (CFSE)-labeled
T cells were cultured with peptide pools (2 μg/mL) or with heat-killed myco-
bacteria. On day 5 CFSElo cells were sorted, and cells were stimulated poly-
clonally with mycobacterial strains or with peptide pools, and libraries were
screened as described above.
Categorization of Antigens. Antigens recognized by two or more donors (i.e.,
epitope reactivity mapping to specific antigens) were classified based on
frequency and magnitude (total SFC) of response. If both the frequency and
magnitude of response were at least fourfold greater in LTBI individuals than
in HCs, the antigen was determined to be LTBI-specific. All other antigens
were categorized as cross-reactive.
NTM-Specific Epitope Identification. A summary of the epitope identification
pipeline is shown in Fig. 5A. All possible 15-mers were selected from 15
strains of NTM [M. abscessus, M. avium 104, M. avium subspecies para-
tuberculosis k 10, M. gilvum PYR-GCK, M. marinum M, M. smegmatis strain
MC2 155, M. sp. JDM601, M. sp. JLS, M. sp. KMS, M. sp. MCS, M. sp. Spyr1
(gilvum), M. ulcerans Agy99, M. vanbaalenii PYR-1, M. colombiense CECT
3035, and M. parascrofulaceum ATCC BAA-614]. Next, all peptides absent
from 21 MTB strains (22) were selected, allowing up to two substitutions.
This selection resulted in a total of 11,532,048 peptides. Of these, all 15-mers
conserved in 5 or more of the 15 strains were selected for a total of 116,070
peptides. The binding affinity of each peptide then was predicted for a
panel of 24 HLA class II alleles (46). Finally, the 1,583 15-mer peptides with
the highest predicted binding promiscuity were synthesized and screened
for recognition in donor samples using an IFN-γ ELISpot assay.
Calculation of dN/dS. Nucleotide sequence concatenates were made for
epitope and nonepitope regions from 21 MTB strains (22). The number of
nonsynonymous nucleotide substitutions (resulting in amino acid sequence
change) per nonsynonymous site (dN) and the number of synonymous nu-
cleotide substitutions (no amino acid change) per synonymous site (dS) were
calculated by the Nei–Gojobori method (47) as implemented in the MEGA5
program (48).
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